Katie Dramond: right. Move quickly and break things as we have been saying a lot in WAID in the past few months. We’ll take a short break, when we go back, what you need to read on WIRED today.
Welcome to Wadi Gharib. I am Katie Dromond, Wire International Editor -in -Chief. Join Business and Industry Director at Wire, Zoë Schiffer. Now, you should read Zoë, before I leave you, listened to what they must completely read, on Wired.com today, unlike the stories that we talked about in this episode.
Zoë Schiffer: Yes. I wish I had a nice, cheerful and luxurious story to talk to you, but I have another story of perdition and depression, and it is before –
Katie Dramond: Oeween.
Zoë Schiffer: I know. It is Caroline Haskins, and she is independent for us, and in fact she just announced that she will join the business office. Very exciting. It is incredible. It is very good. I am very excited. She wrote an article we published yesterday about how Trump and Eileon Musk discounts in the Food and Drug Administration, and therefore another administration witnessed a severe budget and employment discounts already offered the development of drugs. I got this from dozens of SEC files from pharmaceutical companies.
Katie Dramond: So between these SEC files and what you and Emily reported yesterday about freezing these credit cards, it seems that we see federal agencies that stop here in really dependency ways.
Zoë Schiffer: Yes. I mean, it is interesting because pharmaceutical companies, pharmaceutical companies do not even say, “Food and Drug Administration does not agree to our drugs, and therefore these drugs cannot come to the market.” They say that this agency was already very slow in design because the risks are very high when you talk about drugs and medicines. Thus employment discounts, budget discounts. Anxiety is that this will stop. And if you are a pharmaceutical company that decides between continuing to produce an already approved drug or put a lot of time, resources and resources, and the money behind the development of a new drug, you will not get the approval of the FDA (FDA), suddenly you will see less than this type of this type of that, and we will only focus on the money in the current product pipeline. This has serious effects on people who may need these new treatments.
Katie Dramond: Zoë, thank you for all the joy you brought to our program today. Thanks for joining me. Although really, it is really great and very beautiful things for your report and team reports.
Zoë Schiffer: Thank you very much for hosting me.
Katie Dramond: This is our offer for today. We will link all the stories that we talked about today in the display notes. Make sure to review the Thursday episode of Wadi GharibAnd it is all about the Silicon Valley movement in support of the novel. If you like what you heard today, make sure to follow our offer and evaluate it on your favorite PodCast app. If you want to communicate with any of us for questions or comments or display suggestions, write to us on Unsannivalley@wired.com.
Ammar Lal in the total sound mixing this episode. Jake Lumus is our studio engineer. Jordan Bell is our executive product, Condé Nast’s Global Audio head is Chris Bannon. I am Katie Dramund, WAID International Editor -in -Chief.
Good-bye.
